Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applications

Hepatitis

Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial

Gut

Wu X, Quan D, Li W, Wisskirchen K, Wu W, Zhou Y, Liu YP, Wan X, Wang X, Zhang X, Yang L, Zheng M, Zhang K, Protzer U, Du S, Qu X

doi: 10.1136/gutjnl-2025-335456

Gastrointestinal Cancer

Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration

J Hepatol

Lin YJ, Ou DL, Su YY, Hsu CL, Hsiao CF, Ko BS, Chen SC, Wang HW, Wang JH, Wu YM, Jeng YM, Lee WC, Chou SC, Chen TW, Chiu CF, Shiuan Lin Jr, Hsieh CH, Lee CC, Shen YS, Cheng AL, Chen LT, Hsu C

doi: 10.1016/j.jhep.2025.08.035

Gastrointestinal Cancer

Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review

Cancer Treat Rev

Galli E, Patelli G, Villa F, Gri N, Mazzarelli C, Mangoni I, Sgrazzutti C, Ghezzi S, Sartore-Bianchi A, Belli LS, De Carlis L, Vanzulli A, Siena S, Bencardino K

doi: 10.1016/j.ctrv.2025.102908

Gastrointestinal CancerHepatology

Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma

J Hepatol

Yopp A, Chen M, Cheng AL, Kaseb A, Kudo M, Lee HC, Cha E, Hack SP, Lian Q, Spahn J, Wu C, Qin S, Chow PK

doi: 10.1016/j.jhep.2026.01.006

Hepatology

Elevated CircYthdc2 expression is correlated with aggressive features and poor progression-free survival in hepatocellular carcinoma

BMC Gastroenterol

Gong Y, Li X, Wang M

doi: 10.1186/s12876-025-04231-0

HepatitisHepatology

Validation of THCC-RI in the Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study

Clin Gastroenterol Hepatol

Kanwal F, Lopez C, Ning J, Luster M, Reddy KR, Parikh ND, Singal AG, Marrero JA, Chhatwal J, Feng Z, Page-Lester S, Koay EJ, El-Serag HB

doi: 10.1016/j.cgh.2026.01.041

Colonoscopy

Clinical application of pre-rehabilitation concept on comfort colonoscopy in Chinese elderly patients: a randomised controlled trial

BMC Gastroenterol

Zhang L, Lv X, Zhu Q, Zhou J, Huang H, Huang Y, Si C

doi: 10.1186/s12876-025-04059-8

Hepatology

Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A real-world study

Hepatology

Tovoli F, Iavarone M, Cabibbo G, Marra F, Vivaldi C, Dalbeni A, Ponziani FR, Palloni A, Bergamo F, Rimassa L, Lani L, Federico P, Svegliati-Baroni G, Ielasi L, Mazzarelli C, De Lorenzo S, Sacco R, Bruccoleri M, Celsa C, Mastro A, Masi G, Auriemma A, Stella L, Toniutto P, Villani R, Lonardi S, Pressiani T, Piscaglia F, ARTE study group

doi: 10.1097/HEP.0000000000001725

Hepatology

Liver decompensation in patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab: a real-life study

Clin Gastroenterol Hepatol

Stella L, Pallozzi M, Cerrito L, Santopaolo F, Tovoli F, Hollande C, Sidali S, Stefanini B, Campani C, Pellegrini E, Cabibbo G, Marra F, Piscaglia F, Gasbarrini A, Pompili M, Bouattour M, Ponziani FR

doi: 10.1016/j.cgh.2024.12.028

Related content

Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial

Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration

Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: A systematic review

Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma

Elevated CircYthdc2 expression is correlated with aggressive features and poor progression-free survival in hepatocellular carcinoma

Validation of THCC-RI in the Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study

Clinical application of pre-rehabilitation concept on comfort colonoscopy in Chinese elderly patients: a randomised controlled trial

Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A real-world study

Liver decompensation in patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab: a real-life study